'Academic Psychiatry meets Clinical Psychiatry'
31/10/25 @rcpsych
✅Juggling clinical work&&research @lynne_drummond
✅Short&longterm directions in psych&neuro research
✅Clinical work&Academia: What is left to do to bridge the gap?@Derektracy1
Book now
https://t.co/bx6mOuODFt
1/ Just out in @NatureMedicine : we show the opioid system modulates ketamine’s effects in major depressive disorder, with naltrexone pre‑treatment reducing acute glutamatergic activity and acute antidepressant effects. https://t.co/DErg4rqYz3
Most studies on esketamine (and the UK licence) have been as add-on to antidepressants. This study suggests monotherapy may also be effective - although only short term data. As ever the challenge with (es)ketamine comes in the longer term.
Hot off the press!!! Prof Michael Browning from @UniofOxford presenting data from the PAX-D trial, looking a dopaminergic medication to augment the treatment of depression. #BAP2025
It is #BAP2025 and we are at the first symposium of the day! Starting with Dr Thomas Blackmore and preclinical models of psychedelic efficacy. Exciting.
Our new @NIHRMaudsleyBRC CRIS study shows that bipolar disorder is associated with a lower risk of dementia than depression | The British Journal of Psychiatry | Cambridge Core - https://t.co/kMJjTmaCHG
Paper out in @TheBJPsych exploring link between late-life depression vs. anxiety vs. bipolar disorder and dementia.
Compared to depression, anx had same risk but bipolar was lower. We found several demographic & clinical factors influencing risk too.
https://t.co/8XIpqH03w0
@HattyFeldman@TheBJPsych Definitely one possibility! Other things could be (2) survivor effect; (3) BPAD more 'distinguishable' than depression therefore less diagnostic overlap.